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Advances in research
By use of an immunoperoxidase-based staining assay we
investigated the presence of CD1a—a T-cell antigen-
presentation protein—in 113 oesophageal biopsy samples
taken from patients with Barrett’s metaplasia. 84 of the
patients had undergone biopsy once before and had been
given a histological classification of either gastric or intestinal
type metaplasia. The remaining 29 patients had undergone
biopsy more than once; histological assessment confirmed
diagnosis in 16 of these, but the metaplasia of 13 patients had
evolved to dysplasia and neoplasia over time. Biopsy samples
taken from 63 (75%) of the once-only biospy group were
positive for CD1a (41/54 patients with gastric type disease,
figure a; 22/30 patients with intestinal type disease, figure b)
although mucosae from normal stomach and colon tissue
was negative for CD1a in both groups (figure c and figure d,
respectively). In the multiple-biopsy group, 15/16 patients
who had had their diagnosis confirmed were positive for
CD1a (data not shown), wheras only 1/13 with dysplasic or
neoplasic tissue were positive (figure e, dysplastic sample and
figure f, Barrett’s adenocarcinoma). 
We are unable to explain why CD1a is positive in Barret’s
metaplasia and not in normal epithelium, but the presence of
this marker in neoplastic tissue may, if confirmed by
prospective studies, become a useful diagnostic and
prognostic tool indicating a favourable outcome in disease
progression.
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